Companies notified in ~one week
Know a good company?NOMINATE
SEE Track 3 Judges & Speakers
Accelerated Medical Diagnostics (AMD) is developing the PlatinDx assay, which provides direct measurement of in vivo cellular responses to a microdose (~1/100th the therapeutic dose) of platinum-based chemotherapy agents such as carboplatin and oxaliplatin.
Assay Depot has created a web-based application called a Scientific Research Exchange or Marketplace that enables scientists from all over the world to access experts and purchase thousands of research services online.
ASSESSx Technology’s ABATE Qx software is a pain imaging and recording device that collects bio-physiological readings from the skin’s soft-tissue pain sites. The platform offers doctors, nurses and clinicians a way to assess and treat pain cost-effectively and measure soft-tissue inflammation to help a) objectify what patients feel as pain and b) show when the pain is resolved. This pain treatment outcomes data will allow for Evidence Based Medicine/Practices (EBM/EBP).
Astrid’s focus is data management and analysis for genomics research - utilizing core competences in mathematics and information technology. Clients include academic research institutes, pharmaceutical and biotech companies, who are seeking comprehensive IT solutions for diagnostic marker and therapeutic target identification.
Bell Biosystems provides new methods for testing efficacy of cancer drugs and for evaluating cell therapies in animal models. Their tools offer researchers total control of injected cells via imaging, homing, and kill-switch functionalities. The heart of our innovation is the inheritability of these functionalities as cells divide.
Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. The Company’s goal is to predict, prevent, manage and reverse cardiovascular disease by improving patient assessment and management.
Careticker helps patients better prepare before surgery and provide personalized support after surgery for a safe road to recovery. Their applications are procedure-specific, allowing patients to plan, connect and monitor their own needs throughout a healthcare event.
Cypher Genomics provides knowledge through simultaneous utilization of information as well as analytical tools necessary to enable genomic interpretation and discovery.
Cytobank is a web-based platform that manages, shares, and analyzes flow cytometry data. Now used by academic and industrial researchers around the world to manage, share, and analyze their cytometry data, the Cytobank project started as an approach to manage and analyze the large amounts of mass and flow cytometry data generated in Dr. Garry Nolan’s laboratory at Stanford University.
Low-cost and integrated DNA sequencing instrument to enable the democratization and decentralization of sequencing - pushing sequencing from the research environment into the clinical setting.
Goalpost helps prevent and manage chronic disease by changing behavior through social influence, behavioral analytics and medical advice.
Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer.
Microsonic Systems has developed Microprocessor for Life Sciences™ is based on its patented and proprietary Bulk Lateral Ultrasonic (BLU)™ technology increases by 10x the speed and efficiency (yield) of DNA shearing, a critical step in preparing DNA samples for sequencing.
NeuroGeneration is a biotechnology company designing stem cell therapies and biological modifiers for neurodegenerative disorders. Their mission is to provide individualized biotherapeutics and be at the forefront of central nervous system repair and restoration.
Omixon helps clinical and diagnostic labs to adopt next generation sequencing by developing precise and validated NGS data analysis software for the benefit of patients.
OMI is developing novel biomarkers based on clinical and genomic data and is using information generated from multiple sources to develop new treatments for neuro-immune and other diseases.
PLC diagnostics is developing the next generation handheld point of care platform. Based on proprietary waveguide technology, this platform is capable of multiplexing protein and nucleic acid assays. No wash requirements and short turnaround time enable POC monitoring of biomarker panels required for different aspects of personalized medicine.
Portable Genomics™ develops mobile software for comprehensive visualization and use of personal genomic data for informed healthcare planning and lifestyle adjustments in connection with healthcare professionals.
ReSurfX uses novel data generation and utilization technologies to enable better decisions from large volumes of data. They leverage patented, integrative solutions and products to increase Pharma/healthcare productivity as well as to improve sensitivity and accuracy of measurement technologies.
Saladax Biomedical develops and commercializes novel diagnostic assays for the practical delivery of personalized medicine. Saladax’s initial focus is oncology, with a portfolio of 13 chemotherapy drug dose management assays in various stages of development.
Using proprietary hardware, software and call center protocols, SentiCare works with patients on complicated medication regimens to ensure the correct medication is taken at the correct time. Proper adherence leads to improved health outcomes, reduced hospitalization, reduced re-admission within 30-90 days after discharge, and significant cost savings for Healthcare and Senior Housing Providers.
Sofie Biosciences is creating an ever-expanding playing field for molecular imaging, offering a comprehensive range of products from preclinical imaging systems to novel diagnostic PET imaging probes.
Station X develops software products for scientists and clinicians who work with large-scale human genome information in either a research or clinical setting, enabling them to extract maximal biological meaning from complex genomic data.
SV Bio is a diagnostics company, founded to help medical providers improve patient health and outcomes through an understanding of genomics and molecular information.
Syapse is a biomedical data platform helping researchers, providers, and payers use omics to improve medical outcomes.
Talon Biometrics develops a technology for molecular diagnostics, the J-Probe™, offering advantages in sensitivity, selectivity and multiplicity over alternatives. The J-Probe can distinguish and quantify tens of thousands of genetic sequences in a simple single-tube reaction.
Telesofia’s proprietary platform allows health care providers to automatically generate personalized educational videos for their patients, in a way that is friendly, easy to understand and available on any device. The platform is designed to support many applications, such as describing the proper use of their medication, surgical procedure, discharge instructions and more.
telmedx enables doctors and clinicians to remotely see patients via live medical-grade videoTM from patient cell phones. Their HIPAA-compliant telemedicine platforms reduce costs and create revenue opportunities by improving clinician triage, remote diagnosis, follow-up care, drug and protocol compliance, and health status monitoring without a patient clinic visit.
TOMA Biosciences uses the latest genomic sequencing technology and a patented approach to reveal tumor specific information that physicians can use to improve cancer treatment for patients.
uBiome seeks to spark the era of personalized medicine by providing the public with easily accessible information about their own bodies using the latest in high-throughput DNA sequencing technology. In addition, uBiome compares participants’ microbiomes with numerous past studies on the role of the microbiome in health, diet and lifestyle.
Univfy is a privately held company specializing in the development and integration of powerful statistics and computation with an innovative web platform to bring evidence-based, personalized medicine to fertility patients and their healthcare providers. The company was founded in November 2009 by Stanford University professors, Mylene Yao, M.D. and Wing Wong, Ph.D., who had discovered a novel approach to predicting live birth outcomes in in vitro fertilization (IVF).
Focus area: Polymerase Chain Reaction (PCR) systems
Acquired by Bio-Rad for $162M 3 years after starting
DVS Sciences manufactures and globally distributes novel bioanalytical solutions for use in biomarker discovery, biological research and potential future use in clinical applications. The patented multi-parameter technology comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF, and a suite of MAXPAR reagents.
Epizyme discovers and develops small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics.
Genia Technology core technology is the biological nanopore, which reduces the price of sequencing and increases speed, accuracy, and sensitivity by moving away from enzyme-based sequencing methods and optical detection.
Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect disease at its earliest stage.
NextBio has a mission is to integrate the world's genomic data, enabling researchers and clinicians to develop unprecedented biomedical insights and improve human health. NextBio has built a powerful platform to aggregate, correlate and interpret world's collections of private and public genomic data.
Recombinant Data offers life sciences software solutions for translational research. Their standard software packages are toolkits and frameworks for establishing translational research data warehouses and the analytics utilities to maximize use of those data assets.
Telome Health technology will analyze tissue samples to provide customers with accurate and reliable analyses of telomere biology. This data will be generated by research scientists for the research market, and by qualified personnel in a CLIA certified laboratory for the regulated consumer and pharmaceutical markets.
Vision Gate aims to dramatically improve patient health with the world's first, non-invasive, diagnostic test for early lung cancer detection: LuCED™. Additional diagnostic tests for gastroesophageal reflux disease (GERD), bladder cancer and other cancer types will follow.